ZORYVE 0.3% FOAM

What it is

ZORYVE 0.3% FOAM is how the CMS NADAC file names this product. The FDA NDC Directory lists it as roflumilast, under the trade name “ZORYVE”.

FDA gives its dosage form as aerosol, foam and its route as topical.

The labeler, the company named on the label, is Arcutis Biotherapeutics, Inc.

FDA’s Established Pharmacologic Class for it is Phosphodiesterase 4 Inhibitor.

The NADAC file of 2026-10-14 prices it under one NDC (National Drug Code), 80610-0430-60.

NADAC classes it as a brand-name drug (rate-setting class B), and does not mark it as sold over the counter.

What pharmacies pay

Pharmacies pay $922.67 for 60 g (60 × $15.37781 per GM, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.

NADAC’s explanation codes for it: 1, calculated from the most recently completed pharmacy survey; 5, calculated based on package size.

What NADAC measures · NADAC explanation codes

The NDC

• 80610-0430-60 · Arcutis Biotherapeutics, Inc. · $15.37781 per GM · eff. 2026-09-23 filed

Other strengths, forms and brands

7 other products in the NADAC file share the FDA nonproprietary name roflumilast with ZORYVE 0.3% FOAM.

Part D is one average per brand and generic name, over every strength and form.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-01-01, 2026-09-23, 2026-09-30 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18

Compared with its class

Its NADAC price is $15.37781 per GM filed.

Of the 4 other products in FDA’s Phosphodiesterase 4 Inhibitor class priced per GM, 3 have a higher middle NADAC price and 1 a lower one. The one in the middle is ZORYVE 0.3% CREAM, at $15.38387 per GM filed (eff. 2026-09-23).

Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

How the class comparison works

What Medicare paid

Medicare Part D paid $849.16 for 60 g, at an average of $14.15272 per GM in 2024 (2024-01-01 to 2024-12-31) for “Zoryve” and “Roflumilast”, every strength and form sold under that name together (Medicare Part D Spending by Drug, file of 2026-06-25).

That average covers 29,028 Part D claims (fills, including refills) for 2024-01-01 to 2024-12-31, across every maker, strength and form under the name.

Medicare's price is not your price.

What Part D spending measures · Which Medicare figure OpenBill compares · How the spread is worked out

What to ask at the counter

None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.

• What is your cash price for 60 g? Is it lower than what I would pay through my insurance?
• How much is in the package I am getting? This page uses 60 g; your package may hold a different amount.
• If you have Medicare Part D: what is my plan’s copay or coinsurance for it? The Part D average on this page is not what you pay.
• These are questions about price, not medical advice. Do not change or stop a medicine without talking to your prescriber or pharmacist.